Codiak BioSciences, Inc. (CDAK) financial statements (2022 and earlier)

Company profile

Business Address 35 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:76,90088,915
Cash and cash equivalents76,93888,915
Other undisclosed cash, cash equivalents, and short-term investments(38) 
Prepaid expense2,5932,598
Deferred costs200200
Other undisclosed current assets10,4782,045
Total current assets:90,17193,758
Noncurrent Assets
Operating lease, right-of-use asset21,95722,003
Property, plant and equipment23,47931,410
Restricted cash and investments4,1704,170
Other undisclosed noncurrent assets31,893 
Total noncurrent assets:81,49957,583
TOTAL ASSETS:171,670151,341
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,54110,888
Accounts payable1,8382,018
Accrued liabilities9,7038,870
Deferred revenue12,9635,281
Other undisclosed current liabilities2,6611,482
Total current liabilities:27,16517,651
Noncurrent Liabilities
Long-term debt and lease obligation60,31461,500
Long-term debt, excluding current maturities25,43024,960
Operating lease, liability34,88436,540
Liabilities, other than long-term debt30,68657,416
Deferred revenue30,68657,416
Other undisclosed noncurrent liabilities 207
Total noncurrent liabilities:91,000119,123
Total liabilities:118,165136,774
Stockholders' equity
Stockholders' equity attributable to parent53,50514,567
Common stock22
Additional paid in capital378,750302,655
Accumulated deficit(325,247)(288,090)
Total stockholders' equity:53,50514,567
TOTAL LIABILITIES AND EQUITY:171,670151,341

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Revenues22,9352,915
Sublease income1,850861
Gross profit:22,9352,915
Operating expenses(92,484)(93,833)
Operating loss:(69,549)(90,918)
Nonoperating income (expense)32,392(747)
Investment income, nonoperating33,308253
Other nonoperating income1,780906
Interest and debt expense(2,696)(1,906)
Loss before gain (loss) on sale of properties:(39,853)(93,571)
Other undisclosed net income2,6961,906
Net loss attributable to parent:(37,157)(91,665)
Preferred stock dividends and other adjustments (10,831)
Net loss available to common stockholders, diluted:(37,157)(102,496)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss:(37,157)(91,665)
Comprehensive loss:(37,157)(91,665)
Other undisclosed comprehensive loss, net of tax, attributable to parent (43)
Comprehensive loss, net of tax, attributable to parent:(37,157)(91,708)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: